| Background and ObjectiveThe growth of tumor cells can separate form primary site, fix and develop in remote lesion. Growth and metastasis of tumors is a very complex procession, and many genes take part in this course. The KAl1/CD82 gene, the product of which is a member of the transmemberane 4 superfamily(TM4SF), is a suppressor metastasis:as a result, it is inversely associated with tumor progression and is a favorable prognostic factor in some tumors. CD44 is a family of transmembrane glycoproteins expressed in hematopoietic and epithelial cells, and associated with diverse physiological functions such as eell-cell and cell-matrix interactions. It was shown to play a role in the invasive and metastatic properties of tumor cells. Fas(CD95) and its ligand (FasL) signal apoptosis had involved in tissue homeostasis and the elimination of target cells by cytotoxic T cells. Corruption of this signalling pathway in tumour eells, for example by reducing Fas expression or increasing FasL expression, can participate in tumour development and immune escape. Lung carcinoma is one of the mostfrequent causes of ma I i gnancy-re I ated morta I i ty in the wor I d. The major of cases with lung cancer had been disseminated when the diagnosis was ratified. For the other minor ities, the primary locations were still limited, so the surgery was indispensable. Clinical results demonstrated that most of patients with lung cancer had died of metastasis. Though KA11/CD82, CD44 and Fas genes are important roles in regulation of growth and metastasis of lung cancer , there is few investigation in this field. In this study , the expression of CD82 CD44 Fas and DNA content in 45 patients with lung cancer were detected by flow-cytometry. The purpose of this study is to observe the relationship between expression of CD82 CD44, Fas and DNA content in lung carcinomas. It might be provided data for evaluting the prognosis of lung cancer, as well as the potential antiangiogenic therapy for lung cancer.Materials and Methods45 samples were obtained from surgical specimens of patients with lung cancer hospitalized in the First Affiliated Hospital and the Second Affiliated Hospital, Medical College, Zhejiang University and the 117th Hospital of PLA during the period 2002-2004. Among these patients, 33 were male and 12 were female. The average age was 52 1.5 years. The pathological stage was evaluated according to the UICC TNM classifications of primary lung cancer. Histologically, tumors were graded as well, moderately and poorly differentiated. The patients incoluded 23 squamous eell carcinoma, 17 adenocarcinoma and 5 primary large cell carcinoma, 25 with lymph metastasis and 20 without lymph metastasis. All these patients had not received preoperative chemotherapy or radiotherapy. In addition,all these samples were diagnosed to be lung cancer by pathology.The expression of CD82, CD44 Fas and DNA content in 45 patients with lung cancer were detected by flow-cytometry (made by BD corporation), normal control groups (n=30) and 20 patients with benign lesions served as controls.The data were analyzed by statistical package (SPSS 10.0 for w i ndows). The stat i st i ca I methods i nc I uded t-test, ana I ys i s of var i ance and linear correlation.Results1. The expression of CD82 and Fas protein in lung cancer were lower than those in normal control groups and benign lesion groups. The express ion of CD44 prote i n and DNA index (Dl) in lung cancer were higher than those in normal control groups and benign lesion groups. There was no significantly difference between the expression of CD82 CD44 Fas and D1 in normal control groups and benign lesion groups.2. The expression of CD82 and Fas in stage I +II were higher than those in stage III-IV, the expression of CD44 and D1 were lower than those i n stage II1+IV. There was a distinCt statistic difference between CD82 CD44 Fas and D1 in moderate-well histopathological grading and those in poor.The expression of Fas was not related to histopathological grad i ng . The...
|
PDF Full Text Request